Engineered immune cells take on multiple sclerosis and myasthenia gravis
NCT ID NCT07392528
First seen Feb 06, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This early-phase study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty immune cells in people with severe autoimmune diseases like multiple sclerosis, neuromyelitis optica, and myasthenia gravis. Up to 15 participants will receive the treatment to see if it is safe and shows early signs of controlling the disease. The goal is to reduce or stop the immune system from attacking the body, but ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Huanhu Hospital
Tianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.